Saturday 17 October 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
4.43
0.25
−5.34%
Follow MDXG
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 2 | 3 | 4 | 2 | 7 | 5 | 5 |
P/E ratio |
3,650.00 | 21.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.68 | 34.36 | 20.52 |
Altman Z-Score |
10.79 | 20.32 | 3.52 | 4.58 | 2.96 | 2.77 | 1.34 | 8.03 | 14.22 | 9.38 |
P/S ratio |
4.19 | 4.29 | 0.53 | 2.71 | 3.96 | 2.75 | 1.25 | 2.85 | 4.05 | 2.39 |
Altman Z″-Score (non-manufacturers) |
4.48 | 3.10 | (1.40) | (0.38) | (0.66) | 0.65 | (0.86) | 4.02 | 6.87 | 8.06 |
P/FCF ratio |
55.23 | 23.94 | 7.33 | 0.00 | 0.00 | 0.00 | 0.00 | 36.99 | 21.92 | 13.71 |
Beneish M-Score |
(2.88) | (2.75) | (5.60) | 75.28 | (2.43) | (2.77) | (2.46) | (1.09) | (2.83) | (2.68) |
P/Operating CF |
63.12 | 66.02 | 123.22 | (35.06) | (95.74) | (206.23) | (59.63) | 89.39 | 75.28 | 40.09 |
P/B ratio |
6.98 | 18.67 | 3.81 | 23.57 | 0.00 | 8,128.44 | 0.00 | 6.42 | 7.32 | 3.90 |
Price to Tangible BV |
10.36 | 31.46 | 9.42 | 121.99 | 0.00 | 0.00 | 0.00 | 7.77 | 8.73 | 4.49 |
EV/Sales |
4.03 | 4.20 | 0.40 | 2.70 | 3.77 | 2.60 | 1.19 | 2.75 | 3.81 | 2.04 |
EV/EBITDA |
111.83 | 25.79 | 48.96 | 0.00 | 0.00 | 0.00 | 0.00 | 21.80 | 20.47 | 10.82 |
EV/Operating CF |
37.47 | 21.45 | 4.02 | (20.48) | (30.93) | (317.27) | (17.85) | 33.01 | 20.07 | 11.52 |
EV/FCF |
53.18 | 23.46 | 5.58 | (19.39) | (26.88) | (115.34) | (16.46) | 35.66 | 20.59 | 11.68 |
Quick Ratio |
2.00 | 0.61 | 0.64 | 1.51 | 2.39 | 3.03 | 2.50 | 2.95 | 3.51 | 3.76 |
Current Ratio |
2.49 | 1.06 | 1.04 | 1.83 | 2.71 | 3.51 | 3.08 | 3.57 | 4.21 | 4.32 |
Net Debt/EBITDA |
(4.30) | (0.52) | (15.27) | 0.28 | 1.29 | 46.38 | 1.49 | (0.81) | (1.32) | (1.88) |
Debt/Assets |
0.02% | 0.24% | 0.19% | 39.28% | 24.19% | 26.27% | 29.19% | 20.54% | 7.13% | 5.24% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 1.91 | (325.82) | 602.13 | (2.78) | 0.34 | 0.10 | 0.07 |
Asset Turnover |
1.35 | 2.04 | 2.94 | 2.06 | 1.34 | 1.24 | 1.49 | 1.57 | 1.39 | 1.38 |
Operating CF/Net income |
61.15 | 0.97 | (1.19) | 1.54 | 0.36 | 0.12 | 0.49 | 0.46 | 1.56 | 1.52 |
Capex/Depreciation |
(0.99) | (0.88) | (1.46) | (0.25) | (0.50) | (0.56) | (0.37) | (0.58) | (0.28) | (0.07) |
Interest Coverage |
— | — | (7.45) | (4.49) | (5.72) | (1.42) | (2.94) | 5.75 | 58.51 | — |
| 0.32% | 62.60% | (48.57%) | (60.87%) | (486.62%) | 48,297.06% | 410.78% | 93.37% | 25.26% | 21.61% | |
| 0.24% | 41.16% | (24.56%) | (17.64%) | (45.14%) | (8.42%) | (20.47%) | 28.37% | 16.87% | 16.02% | |
ROIC |
0.56% | 61.99% | (51.46%) | (42.68%) | 0.00% | 0.00% | 0.00% | 21.12% | 34.22% | 36.84% |
Return on Tangible Assets |
0.44% | 380.12% | (150.45%) | (37.48%) | (73.81%) | (14.24%) | (37.34%) | 46.50% | 27.86% | 22.29% |
Average Days of Receivables |
110.55 | 0.75 | 0.46 | 39.45 | 66.86 | 61.98 | 58.71 | 61.16 | 58.41 | 66.01 |
Research and Development Expense of Revenue |
6.47% | 5.57% | 4.39% | 3.72% | 4.72% | 4.10% | 4.74% | 3.94% | 3.54% | 3.61% |
Selling, General and Administrative Expense of Revenue |
78.21% | 68.54% | 71.99% | 66.23% | 72.92% | 80.51% | 77.91% | 65.67% | 64.52% | 63.59% |
Intangible Assets out of Total Assets |
0.22 | 0.25 | 0.24 | 0.17 | 0.13 | 0.13 | 0.15 | 0.10 | 0.12 | 0.10 |
Share Based Compensation of Revenue |
8.00% | 6.60% | 4.11% | 4.03% | 6.19% | 5.85% | 4.23% | 5.28% | 4.85% | 3.92% |
Graham Net Nets |
0.07 | 0.00 | 0.00 | (0.01) | (0.04) | (0.06) | (0.16) | 0.07 | 0.09 | 0.19 |
Graham Number |
0.26 | 3.09 | 0.00 | 0.00 | 0.15 | 0.00 | 1.09 | 3.32 | 2.88 | 3.59 |
Earnings Yield |
0.03% | 4.70% | (15.67%) | (3.16%) | (8.48%) | (2.48%) | (11.11%) | 5.08% | 2.91% | 4.87% |
Free Cash Flow Yield |
1.81% | 4.18% | 13.65% | (5.14%) | (3.54%) | (0.82%) | (5.79%) | 2.70% | 4.56% | 7.29% |
Revenue per Share |
2.09 | 3.03 | 3.40 | 2.80 | 2.29 | 2.19 | 2.37 | 2.76 | 2.37 | 2.83 |
Operating CF per Share |
0.23 | 0.59 | 0.34 | (0.37) | (0.28) | (0.02) | (0.16) | 0.23 | 0.45 | 0.50 |
Capex per Share |
(0.07) | (0.05) | (0.09) | (0.02) | (0.04) | (0.03) | (0.01) | (0.02) | (0.01) | (0.01) |
Free Cash Flow per Share |
0.16 | 0.54 | 0.24 | (0.39) | (0.32) | (0.05) | (0.17) | 0.21 | 0.44 | 0.49 |
Cash per Share |
0.32 | 0.26 | 0.43 | 0.65 | 0.89 | 0.79 | 0.58 | 0.70 | 0.71 | 1.12 |
Shareholders Equity per Share |
1.26 | 0.70 | 0.47 | 0.32 | 0.00 | 0.00 | (0.16) | 1.23 | 1.31 | 1.74 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.26 | 0.70 | 0.47 | 0.32 | 0.00 | 0.00 | (0.16) | 1.23 | 1.31 | 1.74 |
Free Cash Flow |
16.80 | 57.54 | 25.80 | (41.63) | (34.82) | (5.45) | (19.41) | 24.79 | 64.52 | 72.97 |
Working Capital |
75.81 | 2.94 | 2.50 | 55.92 | 101.46 | 106.17 | 90.64 | 118.25 | 146.29 | 213.21 |
Capital Expenditures |
(7.05) | (5.40) | (10.00) | (2.22) | (4.55) | (3.47) | (1.51) | (1.99) | (1.68) | (1.03) |
Net Current Asset Value |
66.28 | 1.29 | 0.86 | (9.52) | (41.56) | (39.32) | (55.22) | 67.93 | 121.08 | 191.37 |
EV/EBIT |
1,010.79 | 29.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.82 | 22.57 | 13.34 |
Capex to Sales |
0.03 | 0.02 | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
1,049.70 | 29.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.70 | 24.02 | 15.66 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.52 | 0.44 | 0.39 | 0.73 | 0.80 | 0.68 | 0.52 | 0.49 | 1.02 | 3.16 |
Cash ROIC |
10.04% | 56.66% | 27.16% | (24.62%) | (24.09%) | (3.99%) | (19.80%) | 9.05% | 20.39% | 16.56% |
Accounts Receivable Turnover |
3.67 | 9.47 | 647.05 | 18.25 | 6.38 | 5.59 | 6.36 | 6.63 | 6.36 | 6.37 |
Accounts Payable Turnover |
3.42 | 3.54 | 3.12 | 3.66 | 4.50 | 4.91 | 6.10 | 6.24 | 7.30 | 6.66 |
Inventory Turnover |
2.45 | 2.58 | 2.86 | 3.43 | 4.04 | 3.64 | 3.93 | 3.19 | 2.68 | 2.97 |
Average Days of Payables |
134.92 | 87.61 | 149.11 | 73.79 | 81.34 | 68.02 | 63.87 | 60.45 | 45.02 | 72.63 |
Days of Inventory on Hand |
210.17 | 98.11 | 160.36 | 77.13 | 96.15 | 104.90 | 99.59 | 140.44 | 144.65 | 126.68 |
Average Receivables |
60.45 | 33.90 | 0.56 | 16.40 | 38.91 | 43.28 | 42.09 | 48.48 | 54.85 | 65.77 |
Average Payables |
9.03 | 9.95 | 11.66 | 11.79 | 8.74 | 8.08 | 7.92 | 8.75 | 8.23 | 10.97 |
Average Inventory |
12.64 | 13.64 | 12.73 | 12.55 | 9.73 | 10.88 | 12.29 | 17.10 | 22.41 | 24.57 |
Average Assets |
164.59 | 157.26 | 122.05 | 145.01 | 184.60 | 194.98 | 179.68 | 205.24 | 251.48 | 303.28 |
Average Common Equity |
120.49 | 103.40 | 61.73 | 42.03 | 17.12 | (0.03) | (8.95) | 62.36 | 167.91 | 224.83 |
Columns are period end dates